Editorial Policies

Neoplasia Research has constructed the below editorial policies in accordance to the instructions by the Committee on Publication Ethics (COPE). We shape our publishing platform to comply with the Best Practice Guidelines of the committee and follow its Code of Conduct.


Chief Editors at Neoplasia Research suggest and approve the policies to fulfill the research needs of both readers and authors of the journals. By these actions they mainly aim to bring improvements to the journals and keep the quality of published materials at the highest possible levels.

Editorial Board Members

Chief  Editors may suggest the names of suitably qualified scholars as new editorial board members. The EBMs should keep themselves updated about new policies and developments in their journals which guide them about their expected roles. EBMs make policies that ensure the readers about careful and unbiased external review of submissions from any of the members;  work as representatives of their journals to support and promote the journals; look for the best work and potential authors of the related field of the journal; and may  occasionally be requested to review submissions to the journals maintaining the double-blinded reviewing policy. They are supposed to attend and contribute to the meetings of editorial board addressing the development and future challenges of the journals; or regret promptly with evident reasons in case they are unable to do so.

Copyright Ownership:

For all works published by the Neoplasia Research, articles are considered as the intellectual property of the authors who reserve ownership of the copyright for their article, but allow all readers to download, reuse, reprint, modify, distribute, and/or copy articles in the journals by Neoplasia research provided the original authors and source are appropriately cited.

All Submissions to our journals must be original work, the copyright to which is not previously owned by anyone, elsewhere. Genuine and innovative work is always welcomed along with a strong encouragement for cross- disciplinary approaches. It is the corresponding authors' responsibility to check for possible copyright conflict with the copyright holder and agree to our Publication Ethics and Publication Malpractice Statement.


No Parallel Publication:

When a manuscript is submitted to our journals for consideration parallel submissions of same material, in whole or in part, elsewhere are not allowed; posting of same manuscript on authors institutional website also falls under this restriction. If a case of such subsequent submission comes under publisher’s knowledge, we reserve the right to withdraw publishing rights from authors and co-authors of the article for a substantial time.

Authorship of the Article:

Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant contributions should be listed as co-authors. No responsibilty lies on Neoplasia research regarding the authorship matters including their names or the order of the authors list in case of articles where we sense any dispute regarding the authorship matter Neoplasia Research reserves the right of not publishing that article. The participants who have contributed in certain substantive aspects of the research project, should be acknowledged or listed as contributors. If the article is submitted by a group of researchers, at least one of them should be identified by name and for being responsible for communications related to manuscript publication and for responding to inquiries, if any, about the published article. This author's name and contact information is required be presented as the Corresponding Author on the title page.

Corresponding Authorship:

The corresponding author is the author responsible for communicating with the journal for publication related matters. The corresponding author should ensure that all author agree to be the co-authors, accept their order of names as listed in the submitted article and agree on the content of the article and its submission for publication and have approved the final version of the paper.

Licensing Policy:

With the vision to increase the global exchange of knowledge, Neoplasia Research makes the research freely available to readers worldwide and provides immediate access to all of its published content by choosing the open-access publication policy.
All of our published articles are distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 International License, which permits the readers sharing, adaptation, distribution and reproduction and non-commercial use of our published articles in any medium or format, as long as appropriate credit to the original author(s) and the source is given by the user.

Authors of our published articles retain intellectual property rights of their articles (including research data); attribution rights for their published work; and may share their article provided it contains the end user license and the DOI link to its version in our journal’s archive.

Authors have copyright but license exclusive rights in their article to the publisher*.

Authors of Neoplasia Research are given the right to use their articles, in full or in part, for scholarly but non-commercial purposes including:

  • Distribution of soft/print copies of their articles to known researchers/colleagues for their personal use rather than the Commercial Use
  • Inclusion of their article in a thesis or dissertation that will not be published commercially
  • Distribution for classroom teaching (including electronic/print copies)
  • Use in a subsequent compilation of their works
  • Extending the Article to book-length form
  • For the Preparation of any noncommercial derivative works

Plagiarism Policy:

There is no space for any form of plagiarized material in our journals.

It is noteworthy that all articles submitted to Neoplasia Research are subjected to plagiarism check (copying of any material) on submission. Professionally-recognized soft ware,  iThenticate is  used to evaluate all submissions. Our authors are instructed to assure the journals’ editors about following this policy by providing proper citation of any directly quoted material whether in text form, images, data or ideas. Articles may be highly prone to major revisions or even rejection if their amount of similarity index to other articles in our database is found greater than the allowed limits. We make sure to check all articles against plagiarism just after their submission however, in rare cases of detection of plagiarism after publication of the article, a correction may be issued or the publisher reserves the right to retract the paper and inform the authors’ institutions about their decision to do so.

Disclosure and Conflicts of Interest

All authors should disclose any financial or another substantive conflict of interest in their manuscript that might be construed to influence the results or interpretation of their manuscript. All sources of financial support for the project should be disclosed.

Each submitted article should include a statement about it even when there are no conflicts to disclose.

Protecting Individual Data/Maintaining Confidentiality

The Editor in Chief/editors and any editorial staff must not disclose any information present in a submitted manuscript to anyone else other than the corresponding author, reviewers, potential reviewers, other editorial advisers, and the publisher. everyone  should obey the laws related to this in their own working space. it is necessary to protect the personal information gathered during the research or professional interactions.  in cases where there is a likelihood of persons being recognized by themselves/other readers(e.g. in case studies/photographic illustrations) a written, clearly informed consent for publication should always be gathered from these individuals and presented to the editors. Please not that the consent to take part in a research study or to undergo a treatment should not be considered the same as consent to publish the personal details/images. The JCRU commits strictly to follow its policy on publishing individual data (e.g. identifiable personal details or images) and explains this clearly to authors.

Participants of the research studies have a right to privacy that should not be infringed without their  informed consent. Identifying information should not be published unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. A patient who is identifiable must be shown the manuscript to be published. In case of clinical studies, case reports or patient data presentation it is mandatory that the identifying details of patients should be omitted if they are not essential. If identifying details are required to be published, the patients must be shown the manuscript before publication, in case of altered details with the purpose of protecting patients identity, authors should provide assurance that the alterations do not change the results or conclusions of this paper and Editors should be informed. When informed consent has been obtained, it should be clearly mentioned in the manuscript.

Digital Data Archiving

Neoplasia Research takes full responsibility for the online presence of each published article. To ensure the fulfilment of our commitment in cases of unforeseen events, the content of all journals has been deposited and archived in LOCKSS through the PKP Preservation Network.

Quality Assurance

Editorial members of the journals of Neoplasia Research take all reasonable steps and provide guidance to ensure the quality of the material published by the journals recognizing that the submissions to the journals, acceptable for publication, suitably fit under the aims and standards of the journals and novelty of the research work is worthwhile.

Editorial and Peer Review Processes

Editors of Neoplasia Research are kept informed about timely, fair and unbiased peer review in their journals. Neoplasia Research strive to make sure that the publication material submitted to the journals remains confidential while under reviewing process. The persons involved in editorial process are periodically kept informed about the latest guidelines and recommendations for the reviewing process and the technological advances to assist this process. The editorial members are regularly asked for their advices to bring further improvements in  the review process. If editors are informed about an usual situation during review process of an article they may refer such case  to COPE  provided they find that such situations are not addressed by the   COPE flowcharts. If any case cannot be resolved internally by the EBMs of the journals, the editors have the authority to involve some outside scholar/professional  for guidance as a unanimous decision by EBMs and after taking  approval by the Editor-in-Chief.

Dealing with Possible Misconduct

If a case of suspected misconduct is brought to editors it is their responsibility to follow the guiding rules of COPE flowcharts to persue such cases rather than simply rejecting the articles. This refers to both published as well as unpublished articles. Editors should not simply reject papers that raise concerns about possible misconduct. To resolve the issue it is advised to editors to first seek a reply from the respective authors regarding the suspected misconduct. In case of unsatisfying answers, their employers, institution or a related regulatory body may be approached for investigation.

Though a time-consuming and demanding duty, editors are supposed to take regular feedback from the journals’ relevant staff to make sure that the case of any alleged misconduct has been fully resolved. If a proper investigation into alleged misconduct is not being carried out, editors may take the needful steps to involve other members/EIC in order to obtain a resolution to the problem.

Ensuring the Integrity of the Academic Record

Authors are requested to promptly correct any error, confusing, and inaccurate or misleading statements in the articles with due prominence.

Following of  the COPE guidelines on retractions is ensured during this correction.

Encouraging Debate

Editors at Neoplasia Research encourage rational criticisms of the work submitted to their journals that helps to improve the quality of the articles finally published in their journals. Through the revision procedure, authors are given full opportunity to respond to the critique by peer reviewers. In addition to the positive results of the research authors are instructed to include the negative results and discuss these in their article. Articles that debate/challenge the previous work published by the journals through scientific evidence are also received and considered for publication.


Neoplasia Research editors are open to respond to any complaints reaching them through proper channel and reply to these at their earliest. The complainants are advised to contact the publisher to register their complaint via email at info@neoplasiaresearch.com. Unresolved matters may be taken to COPE by the editors of the respective journal. Our editors follow the procedure set out in the COPE flowchart on complaints.

Direct Marketing:

Journals published by Neoplasia Research do not have any direct marketing activities.